

In this Brief Report in Clinical Infectious Diseases, authors from MSF, Unitaid and the World Health Organization (WHO) discuss the need to increase access to liposomal amphotericin B (L-AmB) for the treatment of cryptococcal meningitis. Cryptococcal meningitis accounts for 1 in 5 AIDS-related deaths globally. WHO guidelines strongly recommend a single high dose of L-AmB as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed from manufacturers and other stakeholders to improve access.